Age: 4.0
Sex: M
Vaccine: HEP, DTAP, HIBV, MMR, OPV, VARCEL
Symptoms: Conjunctivitis, Cough, Diarrhoea, Drug toxicity, Dyspnoea
Clinical narrative: Initial report received from another manufacturer 9/27/06, report number WAES0502USA01392. Information had been received by this reporter secondary to a case in litigation. Follow up information was received by the other manufacturer from a health care professional via medical records, and the source was reported as confidential. A four year old male pt with no known allergies, and a past medical history of candidiasis, rare otitis media, pica and ear infections had received a fifth dose of ActHib, and a fifth dose of Tripedia (trade name Trihibit), lot number 472655, a fourth dose of Orimune, lot number R13662, a second dose of MMR lot number 635124/0399K, and a dose of varicella, lot number 634842/1867J on 8/15/2000. The pt also received a dose of another manufacturers PPD tine test lot number 01757P on 8/20/1997, and a third dose of another manufacturers Hep B lot number 2124A2 on 1/13/1997. It was reported that, at an unspecified time, the pt had experienced toxic mercury exposure secondary to mercury emissions from power plants, the mercury in thimerosal laden products, airborne mercury vapor in the environment, and mercury via the food chain. Per the report, minor male suffered serious and permanent neurological damage which include past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments. The other manufacturer had received medical records from a health care professional, and per those medical records, the pt was diagnosed with autistic spectrum disorder (mild end of spectrum) and possible Aspergers syndrome 80 days post immunization, on 11/03/2000, when the child was four years of age. The pt was referred to a developmental pediatrician who diagnosed the pt with Pervasive developmental disorder. It was believed that there was an unspecified familial etiology. There was no evidence to suggest neither childhood disintegrative disorder or a neurodegenerative process. The pt demonstrated some attention deficits as well as some impulsivity. The pt had experienced some neuromotor abnormalities including a visual motor delay. Approx May 2002, the pt was reported to have a full scale IQ of 95. On the Stanford Binet IV the pt was noted to have a verbal reasoning score of 93 and and abstract visual reasoning score of 89 with a quantitative reasoning score of 106 and a short term memory score of 94.An office note dated 6/19/02 reported the pts vision and hearing had been assessed and felt to be within normal limits. The pt appeared to be struggling with features of an attention deficit disorder including over activity and a short attention span. His physical exam was normal and was reported to have a classic neurological examination. An office note dated 6/9/06 reported the pt was taken to the ER and diagnosed with acute behavioral crisis. The pt was controlled with Risperdal. the pt further experienced at an unspecified amount of time later, an adjustment disorder with mixed disturbance of emotions and was treated with and increased dosage of Risperdal. the pt had a good response to the Risperdal. On 4/29/04, an office note assessed the pt with autism and reported increased symptoms were previously well controlled. At the time of this report, the outcome of the events were unknown. The pt also received prior to the 8/15/00 vaccination, and prior to the diagnosis of Autism Spectrum disorder on 11/03/2000, the following vaccinations, a first IM 0.5cc dose of Hep B manufacturer unk on 1/21/96, a first dose of Trihibit lot number 432655, a first dose of Orimune lot number 433390, and a second dose of Hep B lot number 204BA2 on 8/29/96, a second dose of Trihibit lot number 438088 and a second dose of Orimune lot number 434218 on 11/4/1996, a third dose of Trihibit lot number 426088 and a third dose of Orimune lot number 434218 on 1/13/1997, a first dose of MMR lot number 621081/0287E, and a fourth dose of Trihibit lot number 443263 on 8/29/1997. The other manufacturer received follow up information indication the pt also had a history of rash 1/13/97, abdominal pains with gas 2/3/98, chronic intermittent diarrhoea with pain 6/17/99, possible lactose intolerance 6/17/99, probable increased fat induced gastrointestinal disturbance 7/1/99, cold and upper respiratory infection 3/6/00, stitches places 4/3/00, right leg pain disorder 4/3/02, conjunctivitis 12/19/02, impacted cerumen 2/24/03, astigmatism 1/19/05, cough, trouble breathing, throwing up and mark left forearm dates unk. Upon internal review, the events of pervasive developmental disorder and autism were considered to be other important medical events by the other manufacturer (OMIC).